IL284835B2 - Pharmaceutical combination comprising tno155 and ribociclib - Google Patents
Pharmaceutical combination comprising tno155 and ribociclibInfo
- Publication number
- IL284835B2 IL284835B2 IL284835A IL28483521A IL284835B2 IL 284835 B2 IL284835 B2 IL 284835B2 IL 284835 A IL284835 A IL 284835A IL 28483521 A IL28483521 A IL 28483521A IL 284835 B2 IL284835 B2 IL 284835B2
- Authority
- IL
- Israel
- Prior art keywords
- amino
- per day
- cancer
- pharmaceutically acceptable
- ribociclib
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962804708P | 2019-02-12 | 2019-02-12 | |
| PCT/IB2020/051031 WO2020165734A1 (en) | 2019-02-12 | 2020-02-10 | Pharmaceutical combination comprising tno155 and ribociclib |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL284835A IL284835A (en) | 2021-08-31 |
| IL284835B1 IL284835B1 (en) | 2025-04-01 |
| IL284835B2 true IL284835B2 (en) | 2025-08-01 |
Family
ID=69724013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL284835A IL284835B2 (en) | 2019-02-12 | 2020-02-10 | Pharmaceutical combination comprising tno155 and ribociclib |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12343344B2 (enExample) |
| EP (1) | EP3923941B1 (enExample) |
| JP (1) | JP7493521B2 (enExample) |
| KR (1) | KR20210126653A (enExample) |
| CN (1) | CN113382731A (enExample) |
| AU (3) | AU2020222296B2 (enExample) |
| BR (1) | BR112021015632A2 (enExample) |
| CA (1) | CA3127286A1 (enExample) |
| CL (1) | CL2021002099A1 (enExample) |
| IL (1) | IL284835B2 (enExample) |
| MX (1) | MX2021009563A (enExample) |
| TW (1) | TWI831916B (enExample) |
| WO (1) | WO2020165734A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120208856A (zh) | 2018-09-29 | 2025-06-27 | 诺华股份有限公司 | 用于抑制shp2活性的化合物和组合物的制造 |
| US12138262B2 (en) | 2018-09-29 | 2024-11-12 | Novartis Ag | Process of manufacture of a compound for inhibiting the activity of SHP2, as well as products resulting from acid addition |
| WO2020072656A1 (en) | 2018-10-03 | 2020-04-09 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
| US20220160706A1 (en) * | 2019-02-12 | 2022-05-26 | Novartis Ag | Pharmaceutical combination comprising tno155 and a pd-1 inhibitor |
| AU2021293228A1 (en) | 2020-06-18 | 2023-02-09 | Revolution Medicines, Inc. | Methods for delaying, preventing, and treating acquired resistance to RAS inhibitors |
| KR20230038197A (ko) | 2020-07-08 | 2023-03-17 | 노파르티스 아게 | Shp2의 활성 억제를 위한 화합물 및 조성물의 제조 |
| US20250195521A1 (en) | 2020-09-03 | 2025-06-19 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| IL301298A (en) | 2020-09-15 | 2023-05-01 | Revolution Medicines Inc | Indole derivatives as RAS inhibitors in cancer therapy |
| EP4334324A1 (en) | 2021-05-05 | 2024-03-13 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| US20240238284A1 (en) * | 2021-05-05 | 2024-07-18 | Novartis Ag | Compounds and compositions for the treatment of mpnst |
| WO2022235870A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
| US12390469B2 (en) * | 2021-05-05 | 2025-08-19 | Huyabio International, Llc | SHP2 inhibitor monotherapy and uses thereof |
| TW202309052A (zh) | 2021-05-05 | 2023-03-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| US20240293422A1 (en) * | 2021-06-24 | 2024-09-05 | Erasca, Inc. | Shp2 and cdk4/6 inhibitors combination therapies for the treatment of cancer |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| TW202342040A (zh) | 2022-02-21 | 2023-11-01 | 瑞士商諾華公司 | 藥物配製物 |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| KR20250022133A (ko) | 2022-06-10 | 2025-02-14 | 레볼루션 메디슨즈, 인크. | 거대고리 ras 억제제 |
| WO2024115680A1 (en) | 2022-12-01 | 2024-06-06 | Krka, D.D., Novo Mesto | Ribociclib salts and formulations thereof |
| KR20240097396A (ko) | 2022-12-20 | 2024-06-27 | 재단법인대구경북과학기술원 | 리보시클립을 유효성분으로 포함하는 신경염증 또는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물 |
| KR20250164828A (ko) | 2023-03-30 | 2025-11-25 | 레볼루션 메디슨즈, 인크. | Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도 |
| WO2024211663A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| AU2024243852A1 (en) | 2023-04-07 | 2025-11-06 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| KR20250172857A (ko) | 2023-04-14 | 2025-12-09 | 레볼루션 메디슨즈, 인크. | Ras 억제제의 결정형 |
| KR20250169290A (ko) | 2023-04-14 | 2025-12-02 | 레볼루션 메디슨즈, 인크. | Ras 억제제의 결정형, 이를 함유하는 조성물 및 이의 사용 방법 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015107495A1 (en) * | 2014-01-17 | 2015-07-23 | Novartis Ag | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2 |
| WO2018130928A1 (en) * | 2017-01-10 | 2018-07-19 | Novartis Ag | Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8685980B2 (en) | 2008-08-22 | 2014-04-01 | Novartis Ag | Pyrrolopyrimidine compounds and their uses |
| BR112020004246A2 (pt) * | 2017-09-07 | 2020-09-01 | Revolution Medicines, Inc. | composições inibidoras de shp2 e métodos para o tratamento de câncer |
| EP3897659A4 (en) | 2018-12-17 | 2022-09-07 | Lunella Biotech, Inc. | Triple combination therapies for anti-aging |
| AU2019403048B2 (en) | 2018-12-17 | 2025-01-23 | Lunella Biotech, Inc. | Triple combination therapies for targeting mitochondria and killing cancer stem cells |
| EP4249000A3 (en) | 2019-02-12 | 2023-12-27 | Novartis AG | Pharmaceutical combination comprising tno155 and a krasg12c inhibitor |
| US20220160706A1 (en) | 2019-02-12 | 2022-05-26 | Novartis Ag | Pharmaceutical combination comprising tno155 and a pd-1 inhibitor |
-
2020
- 2020-02-10 CN CN202080012520.8A patent/CN113382731A/zh active Pending
- 2020-02-10 WO PCT/IB2020/051031 patent/WO2020165734A1/en not_active Ceased
- 2020-02-10 TW TW109104042A patent/TWI831916B/zh active
- 2020-02-10 BR BR112021015632-1A patent/BR112021015632A2/pt unknown
- 2020-02-10 IL IL284835A patent/IL284835B2/en unknown
- 2020-02-10 JP JP2021546211A patent/JP7493521B2/ja active Active
- 2020-02-10 KR KR1020217028654A patent/KR20210126653A/ko not_active Ceased
- 2020-02-10 MX MX2021009563A patent/MX2021009563A/es unknown
- 2020-02-10 EP EP20707827.0A patent/EP3923941B1/en active Active
- 2020-02-10 CA CA3127286A patent/CA3127286A1/en active Pending
- 2020-02-10 AU AU2020222296A patent/AU2020222296B2/en active Active
- 2020-02-10 US US17/430,219 patent/US12343344B2/en active Active
-
2021
- 2021-08-10 CL CL2021002099A patent/CL2021002099A1/es unknown
-
2023
- 2023-06-15 AU AU2023203751A patent/AU2023203751A1/en not_active Abandoned
-
2025
- 2025-05-23 AU AU2025203816A patent/AU2025203816A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015107495A1 (en) * | 2014-01-17 | 2015-07-23 | Novartis Ag | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2 |
| WO2018130928A1 (en) * | 2017-01-10 | 2018-07-19 | Novartis Ag | Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor |
Non-Patent Citations (1)
| Title |
|---|
| TRIPATHY D ET AL., RIBOCICLIB (LEE011): MECHANISM OF ACTION AND CLINICAL IMPACT OF THIS SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITOR IN VARIOUS SOLID TUMORS, 28 March 2017 (2017-03-28) * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3923941A1 (en) | 2021-12-22 |
| AU2020222296B2 (en) | 2023-04-06 |
| US12343344B2 (en) | 2025-07-01 |
| AU2020222296A1 (en) | 2021-08-05 |
| CL2021002099A1 (es) | 2022-04-18 |
| EP3923941B1 (en) | 2025-12-03 |
| CA3127286A1 (en) | 2020-08-20 |
| JP2022519375A (ja) | 2022-03-23 |
| AU2023203751A1 (en) | 2023-07-13 |
| IL284835B1 (en) | 2025-04-01 |
| AU2025203816A1 (en) | 2025-06-12 |
| JP7493521B2 (ja) | 2024-05-31 |
| WO2020165734A1 (en) | 2020-08-20 |
| BR112021015632A2 (pt) | 2021-10-05 |
| US20220160707A1 (en) | 2022-05-26 |
| MX2021009563A (es) | 2021-09-08 |
| KR20210126653A (ko) | 2021-10-20 |
| TWI831916B (zh) | 2024-02-11 |
| IL284835A (en) | 2021-08-31 |
| CN113382731A (zh) | 2021-09-10 |
| TW202045171A (zh) | 2020-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12343344B2 (en) | Pharmaceutical combination comprising TNO155 and ribociclib | |
| EP4249000A2 (en) | Pharmaceutical combination comprising tno155 and a krasg12c inhibitor | |
| AU2021267213B2 (en) | Pharmaceutical combination comprising TNO155 and nazartinib | |
| US20240238284A1 (en) | Compounds and compositions for the treatment of mpnst | |
| RU2813111C2 (ru) | Фармацевтическая комбинация, содержащая tno155 и рибоциклиб | |
| HK40060474A (en) | Pharmaceutical combination comprising tno155 and ribociclib | |
| US20240180923A1 (en) | Methods of treating disorders with ulk inhibitors |